<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39243580</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1877-783X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><PubDate><Year>2024</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Cancer epidemiology</Title><ISOAbbreviation>Cancer Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009-2021.</ArticleTitle><Pagination><StartPage>102659</StartPage><MedlinePgn>102659</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canep.2024.102659</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1877-7821(24)00138-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Due to the rarity of pancreatic neuroendocrine neoplasms, only few population-representative studies on incidence and survival have been conducted. The aim was to provide up-to-date nationwide incidence and relative survival estimates of neuroendocrine (NE) neoplasms overall, NE tumors (NETs), NE carcinomas (NECs), and mixed NE neoplasms (MiNEN).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We distinguished between pancreatic NETs (functioning versus non-functioning), NECs and mixed NE neoplasms and analyzed data from 2009 through 2021 from all German cancer registries covering a population of more than 80 million. We calculated crude and age-standardized incidence rates and 5-year relative survival estimates (RS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall 6474, 4217, and 243 patients with pancreatic NETs, NECs, and mixed NE neoplasms, respectively were registered. While the age-standardized incidence of NETs has increased (+16.4 % per year, 95 %CI 12.2;20.7), the incidence of NEC has fallen (about -6.4 % per year, 95 %CI -8.0; -4.8). The crude RS was 77.7 % (standard error [SE] 0.9) for non-functioning NETs, 90.3 % for functioning NETs (SE 3.9), and 18.5 % (SE 3.9) for MiNEN. Large and small cell NECs had a low RS (9.1 % and 6.9 %, respectively). RS for G1 NETs was 88.2 %, while it was only 36.6 % for G3 NETs. Localized NETs had a RS of 92.8 %, while distant metastatic NETs had a RS of 45.0 %.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The incidence of pancreatic NETs has increased markedly in Germany in the period 2009-2021. Subgroups of NETs (G1 grading or localized stage) have an excellent prognosis. RS of MiNEN is more similar to NECs than NETs.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Germany; School of Public Health, Department of Epidemiology, Boston University, Boston, USA; Cancer Registry of North Rhine-Westphalia, Bochum, Germany. Electronic address: andreas.stang@krebsregister.nrw.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wellmann</LastName><ForeName>Ina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cancer Registry of North Rhine-Westphalia, Bochum, Germany. Electronic address: ina.wellmann@krebsregister.nrw.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holleczek</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Saarland Cancer Registry, Neugeländstr. 9, Saarbrücken 6617, Germany. Electronic address: b.holleczek@krebsregister.saarland.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim-Wanner</LastName><ForeName>Soo-Zin</ForeName><Initials>SZ</Initials><AffiliationInfo><Affiliation>Hessian Cancer Registry, Hessian Office of Health and Care, Frankfurt am Main, Germany. Electronic address: soo-zin.kim-wanner@hlfgp.hessen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller-Nordhorn</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bavarian Cancer Registry, Bavarian Health and Food Safety Authority, Munich, Germany. Electronic address: Jacqueline.Mueller-Nordhorn@lgl.bayern.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sirri</LastName><ForeName>Eunice</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Epidemiological Cancer Registry of Lower Saxony (EKN), Registry Division, Oldenburg, Germany. Electronic address: eunice.sirri@offis-care.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wittenberg</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Clinical Cancer Registry Saxony-Anhalt, Halle (Saale) 06112, Germany. Electronic address: i.wittenberg@kkr-lsa.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siveke</LastName><ForeName>Jens T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>German Cancer Consortium (DKTK), partner site Essen, a partnership between German Cancer Research Center (DKFZ) and University Hospital Essen, Germany; Bridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Electronic address: Jens.siveke@uk-essen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kajüter</LastName><ForeName>Hiltraud</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cancer Registry of North Rhine-Westphalia, Bochum, Germany. Electronic address: Hiltraud.kajueter@krebsregister.nrw.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>German Network of Cancer Registries</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Cancer Epidemiol</MedlineTA><NlmUniqueID>101508793</NlmUniqueID><ISSNLinking>1877-7821</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">(MeSH)</Keyword><Keyword MajorTopicYN="N">Carcinoma</Keyword><Keyword MajorTopicYN="N">Germany</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Neuroendocrine</Keyword><Keyword MajorTopicYN="N">Neuroendocrine tumors</Keyword><Keyword MajorTopicYN="N">Registries</Keyword><Keyword MajorTopicYN="N">Survival analysis</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J.T.S. receives honoraria as consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Immunocore, MSD Sharp Dohme, Novartis, Roche/Genentech, and Servier. His institution receives research funding from Abalos Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisbach Bio, and Roche/Genentech; he holds ownership in FAPI Holding (&lt; 3 %); all outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>8</Day><Hour>13</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>8</Day><Hour>13</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>7</Day><Hour>18</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39243580</ArticleId><ArticleId IdType="doi">10.1016/j.canep.2024.102659</ArticleId><ArticleId IdType="pii">S1877-7821(24)00138-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>